Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Robert De Jager

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Plos One|November 2, 2022
Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival timesHoward W Bruckner, Fred Bassali, Elisheva Dusowitz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 7, 2018
Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxiaTheresa Zesiewicz, Frederic Heerinckx, Robert De Jager, et al.
Frontiers in Oncology|July 9, 2024
Cholangiocarcinoma, sequential chemotherapy, and prognostic testsHoward W Bruckner, Robert De Jager, Elisheva Knopf, et al.
Investigational New Drugs|September 1, 2005
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancerJaffer A Ajani, Chris Takimoto, Carlos R Becerra, et al.
American Journal of Clinical Oncology|August 3, 2005
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancersGhassan K Abou-Alfa, Eric K Rowinsky, Yehuda Z Patt, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Plos One|November 2, 2022
Actionable tests and treatments for patients with gastrointestinal cancers and historically short median survival timesHoward W Bruckner, Fred Bassali, Elisheva Dusowitz, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|April 7, 2018
Randomized, clinical trial of RT001: Early signals of efficacy in Friedreich's ataxiaTheresa Zesiewicz, Frederic Heerinckx, Robert De Jager, et al.
Frontiers in Oncology|July 9, 2024
Cholangiocarcinoma, sequential chemotherapy, and prognostic testsHoward W Bruckner, Robert De Jager, Elisheva Knopf, et al.
Investigational New Drugs|September 1, 2005
A phase II clinical and pharmacokinetic study of intravenous exatecan mesylate (DX-8951f) in patients with untreated metastatic gastric cancerJaffer A Ajani, Chris Takimoto, Carlos R Becerra, et al.
American Journal of Clinical Oncology|August 3, 2005
A Phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancersGhassan K Abou-Alfa, Eric K Rowinsky, Yehuda Z Patt, et al.
Pageof 1